 [1m([0morchestrator-angioedema-MINOCYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes MINOCYCLINE increase or decrease the risk of angioedema?[0m
 [1m([0morchestrator-angioedema-MINOCYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-angioedema-MINOCYCLINE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-angioedema-MINOCYCLINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does MINOCYCLINE increase the risk of angioedema?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-angioedema-MINOCYCLINE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes MINOCYCLINE increase the risk of angioedema?[0m
 [1m([0morchestrator-angioedema-MINOCYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-angioedema-MINOCYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-angioedema-MINOCYCLINE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes MINOCYCLINE increase the risk of angioedema?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does MINOCYCLINE increase the risk of angioedema?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"MINOCYCLINE"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: MINOCYCLINE: adverse_reactions: [0m[1;31m6[0m[31m ADVERSE REACTIONS The most commonly observed adverse reactions [0m[1;31m([0m[31mincidence ‚â• [0m[1;31m5[0m[31m%[0m[1;31m)[0m[31m are headache, fatigue, dizziness, and pruritus. [0m[1;31m([0m[31m [0m[1;31m6.1[0m[31m [0m[1;31m)[0m[31m To report SUSPECTED [0m
[31mADVERSE REACTIONS, contact Sandoz Inc., at [0m[1;31m1[0m[31m-[0m[1;31m800[0m[31m-[0m[1;31m525[0m[31m-[0m[1;31m8747[0m[31m or FDA at [0m[1;31m1[0m[31m-[0m[1;31m800[0m[31m-FDA-[0m[1;31m1088[0m[31m or www.fda.gov/medwatch . [0m[1;31m6.1[0m[31m Clinical Trial Experience Because clinical trials are conducted under widely varying [0m
[31mconditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug, and may not reflect the rates observed in [0m
[31mpractice. The following table summarizes selected adverse reactions reported in clinical trials at a rate of ‚â•[0m[1;31m1[0m[31m% for minocycline hydrochloride extended-release tablets. MINOCYCLINE: adverse_reactions:[0m
[31mTable [0m[1;31m2[0m[31m: Selected Treatment-Emergent Adverse Reactions in at least [0m[1;31m1[0m[31m% of Clinical Trial Subjects Adverse Reactions Minocycline Hydrochloride Extended-Release Tablets [0m[1;31m([0m[1;31m1[0m[31m mg/kg[0m[1;31m)[0m[31m [0m[31mN[0m[31m=[0m[1;31m674[0m[1;31m([0m[31m%[0m[1;31m)[0m[31m Placebo [0m
[31mN[0m[31m=[0m[1;31m364[0m[1;31m([0m[31m%[0m[1;31m)[0m[31m At least one treatment-emergent event [0m[1;31m379[0m[1;31m([0m[1;31m56[0m[1;31m)[0m[31m [0m[1;31m197[0m[1;31m([0m[1;31m54[0m[1;31m)[0m[31m Headache [0m[1;31m152[0m[31m [0m[1;31m([0m[1;31m23[0m[1;31m)[0m[31m [0m[1;31m83[0m[31m [0m[1;31m([0m[1;31m23[0m[1;31m)[0m[31m Fatigue [0m[1;31m62[0m[31m [0m[1;31m([0m[1;31m9[0m[1;31m)[0m[31m [0m[1;31m24[0m[31m [0m[1;31m([0m[1;31m7[0m[1;31m)[0m[31m Dizziness [0m[1;31m59[0m[31m [0m[1;31m([0m[1;31m9[0m[1;31m)[0m[31m [0m[1;31m17[0m[31m [0m[1;31m([0m[1;31m5[0m[1;31m)[0m[31m Pruritus [0m[1;31m31[0m[31m [0m[1;31m([0m[1;31m5[0m[1;31m)[0m[31m [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m4[0m[1;31m)[0m[31m Malaise [0m[1;31m26[0m[31m [0m[1;31m([0m[1;31m4[0m[1;31m)[0m[31m [0m[1;31m9[0m[31m [0m[1;31m([0m[1;31m3[0m[1;31m)[0m[31m Mood alteration [0m[1;31m17[0m[31m [0m
[1;31m([0m[1;31m3[0m[1;31m)[0m[31m [0m[1;31m9[0m[31m [0m[1;31m([0m[1;31m3[0m[1;31m)[0m[31m Somnolence [0m[1;31m13[0m[31m [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m [0m[1;31m3[0m[31m [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m Urticaria [0m[1;31m10[0m[31m [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m0[0m[1;31m)[0m[31m Tinnitus [0m[1;31m10[0m[31m [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m [0m[1;31m5[0m[31m [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m Arthralgia [0m[1;31m9[0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m [0m[1;31m2[0m[1;31m([0m[1;31m0[0m[1;31m)[0m[31m MINOCYCLINE: adverse_reactions: Vertigo [0m[1;31m8[0m[31m [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m [0m[1;31m3[0m[31m [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m Dry mouth [0m[1;31m7[0m[31m [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m [0m[1;31m5[0m[31m [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m Myalgia [0m[1;31m7[0m[31m [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m [0m[1;31m6.2[0m[31m [0m
[31mPostmarketing Experience Adverse reactions that have been reported with minocycline hydrochloride use in a variety of indications include: Skin and hypersensitivity reactions: fixed drug eruptions, [0m
[31mbalanitis, erythema multiforme, Stevens-Johnson syndrome, anaphylactoid purpura, photosensitivity, pigmentation of skin and mucous membranes, hypersensitivity reactions, angioneurotic edema, [0m
[31manaphylaxis, DRESS syndrome [0m[31m. Autoimmune conditions: polyarthralgia, pericarditis, exacerbation of systemic lupus, pulmonary infiltrates with eosinophilia, transient lupus-like syndrome. MINOCYCLINE: [0m
[31madverse_reactions: Central nervous system: pseudotumor cerebri, bulging fontanels in infants, decreased hearing. Endocrine: brown-black microscopic thyroid discoloration, abnormal thyroid function. [0m
[31mOncology : thyroid cancer. Oral: glossitis, dysphagia, tooth discoloration. Gastrointestinal : enterocolitis, pancreatitis, hepatitis, liver failure. Renal : reversible acute renal failure. Hematology[0m
[31m: hemolytic anemia, thrombocytopenia, eosinophilia. Preliminary studies suggest that use of minocycline may have deleterious effects on human spermatogenesis [0m[31m.         [0m
[31mSOURCE:MINOCYCLINE label[0m


[31mCONTENT: MINOCYCLINE: spl_patient_package_insert: See ‚ÄúWhat should I tell my doctor before taking minocycline hydrochloride extended-release tablets?‚Äù ‚Ä¢ Intestine infection [0m[1;31m([0m[31mpseudomembranous colitis[0m[1;31m)[0m[31m.[0m
[31mPseudomembranous colitis can happen with most antibiotics, including minocycline hydrochloride extended-release tablets. Call your doctor right away if you get watery diarrhea, diarrhea that does not [0m
[31mgo away, or bloody stools. ‚Ä¢ Serious liver problems . Stop taking minocycline hydrochloride extended-release tablets and call your doctor right away if you get any of the following symptoms of liver [0m
[31mproblems: ‚àò loss of appetite ‚àò tiredness ‚àò diarrhea ‚àò yellowing of your skin or the whites of your eyes ‚àò unexplained bleeding ‚àò confusion ‚àò sleepiness ‚Ä¢ Central nervous system effects. See ‚ÄúWhat [0m
[31mshould I avoid while taking minocycline hydrochloride extended-release tablets? MINOCYCLINE: spl_patient_package_insert: Central nervous system effects such as light headedness, dizziness, and a [0m
[31mspinning feeling [0m[1;31m([0m[31mvertigo[0m[1;31m)[0m[31m may go away during your treatment with minocycline hydrochloride extended-release tablets or if treatment is stopped. ‚Ä¢ Benign intracranial hypertension, also called [0m
[31mpseudotumor cerebri . This is a condition where there is high pressure in the fluid around the brain. This swelling may lead to vision changes and permanent vision loss. Stop taking minocycline [0m
[31mhydrochloride extended-release tablets and tell your doctor right away if you have blurred vision, vision loss, or unusual headaches. Immune system reactions including a lupus-like syndrome, [0m
[31mhepatitis, and inflammation of blood or lymph vessels [0m[1;31m([0m[31mvasculitis[0m[1;31m)[0m[31m. Using minocycline hydrochloride extended-release tablets for a long time to treat acne may cause immune system reactions. Tell your [0m
[31mdoctor right away if you get a fever, rash, joint pain, or body weakness. MINOCYCLINE: spl_patient_package_insert: Your doctor may do tests to check your blood for immune system reactions. ‚Ä¢ Serious [0m
[31mrash and allergic reactions . Minocycline hydrochloride extended-release tablets may cause a serious rash and allergic reactions that may affect parts of your body such as your liver, lungs, kidneys [0m
[31mand heart. Sometimes these can lead to death. MINOCYCLINE: spl_patient_package_insert: ‚Ä¢ Stop taking minocycline hydrochloride extended-release tablets and get medical help right away if you have any [0m
[31mof these symptoms: ‚àò skin rash, hives, sores in your mouth, or your skin blisters and peels ‚àò swelling of your face, eyes, lips, tongue, or throat ‚àò trouble swallowing or breathing ‚àò blood in your [0m
[31murine ‚àò fever, yellowing of the skin or the whites of your eyes, dark colored urine ‚àò pain on the right side of the stomach area [0m[1;31m([0m[31mabdominal pain[0m[1;31m)[0m[31m ‚àò chest pain or abnormal heartbeats ‚àò swelling in your[0m
[31mlegs, ankles and feet ‚àò darkening of your nails, skin, eyes, scars, teeth, and gums. The most common side effects of minocycline hydrochloride extended-release tablets include: ‚Ä¢ headache ‚Ä¢ tiredness [0m
[31m‚Ä¢ dizziness or spinning feeling ‚Ä¢ itching Call your doctor if you have a side effect that bothers you or that does not go away. MINOCYCLINE: spl_patient_package_insert: Your doctor may do tests to [0m
[31mcheck you for side effects during treatment with minocycline hydrochloride extended-release tablets. These are not all the side effects with minocycline hydrochloride extended-release tablets. Ask [0m
[31myour doctor or pharmacist for more information. Call your doctor for medical advice about side effects. You may report side effects to Sandoz Inc. at [0m[1;31m1[0m[31m-[0m[1;31m800[0m[31m-[0m[1;31m525[0m[31m-[0m[1;31m8747[0m[31m or FDA at [0m[1;31m1[0m[31m-[0m[1;31m800[0m[31m-FDA-[0m[1;31m1088[0m[31m. How [0m
[31mshould I store minocycline hydrochloride extended-release tablets? ‚Ä¢ Store minocycline hydrochloride extended-release tablets at 20¬∫ to 25¬∫C [0m[1;31m([0m[31m68¬∫ to 77¬∫F[0m[1;31m)[0m[31m [0m[31m. ‚Ä¢ Keep minocycline hydrochloride [0m
[31mextended-release tablets in the container that it comes in and keep container tightly closed. ‚Ä¢ Keep minocycline hydrochloride extended-release tablets dry.         [0m
[31mSOURCE:MINOCYCLINE label[0m


[31mCONTENT: MINOCYCLINE: warnings_and_cautions: Bulging fontanels have been associated with the use of tetracyclines in infants. Although signs and symptoms of pseudotumor cerebri resolve after [0m
[31mdiscontinuation of treatment, the possibility for permanent sequelae such as visual loss that may be permanent or severe exists. Patients should be questioned for visual disturbances prior to [0m
[31minitiation of treatment with tetracyclines. If visual disturbance occurs during treatment, patients should be checked for papilledema. Concomitant use of isotretinoin and minocycline should be avoided[0m
[31mbecause isotretinoin, a systemic retinoid, is also known to cause pseudotumor cerebri. [0m[1;31m5.7[0m[31m Autoimmune Syndromes Tetracyclines have been associated with the development of autoimmune syndromes. The [0m
[31mlong-term use of minocycline in the treatment of acne has been associated with drug-induced lupus-like syndrome, autoimmune hepatitis and vasculitis. MINOCYCLINE: warnings_and_cautions: Sporadic cases[0m
[31mof serum sickness have presented shortly after minocycline use. Symptoms may be manifested by fever, rash, arthralgia, and malaise. In symptomatic patients, liver function tests, ANA, CBC, and other [0m
[31mappropriate tests should be performed to evaluate the patients. Use of all tetracycline-class drugs should be discontinued immediately. [0m[1;31m5.8[0m[31m Photosensitivity Photosensitivity manifested by an [0m
[31mexaggerated sunburn reaction has been observed in some individuals taking tetracyclines. This has been reported rarely with minocycline. Patients should minimize or avoid exposure to natural or [0m
[31martificial sunlight [0m[1;31m([0m[31mtanning beds or UVA/B treatment[0m[1;31m)[0m[31m while using minocycline. If patients need to be outdoors while using minocycline, they should wear loose-fitting clothes that protect skin from [0m
[31msun exposure and discuss other sun protection measures with their physician. [0m[1;31m5[0m[31m. MINOCYCLINE: warnings_and_cautions: [0m[1;31m9[0m[31m Serious Skin/Hypersensitivity Reaction Cases of anaphylaxis, serious skin [0m
[31mreactions [0m[1;31m([0m[31me.g. Stevens Johnson syndrome[0m[1;31m)[0m[31m, erythema multiforme, and drug rash with eosinophilia and systemic symptoms [0m[1;31m([0m[31mDRESS[0m[1;31m)[0m[31m syndrome have been reported postmarketing with minocycline use in patients[0m
[31mwith acne. DRESS syndrome consists of cutaneous reaction [0m[1;31m([0m[31msuch as rash or exfoliative dermatitis[0m[1;31m)[0m[31m, eosinophilia, and one or more of the following visceral complications such as: hepatitis, [0m
[31mpneumonitis, nephritis, myocarditis, and pericarditis. Fever and lymphadenopathy may be present. In some cases, death has been reported. If this syndrome is recognized, the drug should be discontinued[0m
[31mimmediately. [0m[1;31m5.10[0m[31m Tissue Hyperpigmentation Tetracycline class antibiotics are known to cause hyperpigmentation. MINOCYCLINE: warnings_and_cautions: Tetracycline therapy may induce hyperpigmentation in[0m
[31mmany organs, including nails, bone, skin, eyes, thyroid, visceral tissue, oral cavity [0m[1;31m([0m[31mteeth, mucosa, alveolar bone[0m[1;31m)[0m[31m, sclerae and heart valves. Skin and oral pigmentation has been reported to occur [0m
[31mindependently of time or amount of drug administration, whereas other tissue pigmentation has been reported to occur upon prolonged administration. Skin pigmentation includes diffuse pigmentation as [0m
[31mwell as over sites of scars or injury. [0m[1;31m5.11[0m[31m Development of Drug Resistant Bacteria Bacterial resistance to the tetracyclines may develop in patients using minocycline hydrochloride extended-release [0m
[31mtablets, therefore, the susceptibility of bacteria associated with infection should be considered in selecting antimicrobial therapy. Because of the potential for drug-resistant bacteria to develop [0m
[31mduring the use of minocycline hydrochloride extended-release tablets, it should be used only as indicated. [0m[1;31m5[0m[31m. MINOCYCLINE: warnings_and_cautions: [0m[1;31m12[0m[31m Superinfection As with other antibiotic [0m
[31mpreparations, use of minocycline hydrochloride extended-release tablets may result in overgrowth of nonsusceptible organisms, including fungi. If superinfection occurs, minocycline hydrochloride [0m
[31mextended-release tablets should be discontinued and appropriate therapy instituted. [0m[1;31m5.13[0m[31m Laboratory Monitoring Periodic laboratory evaluations of organ systems, including hematopoietic renal and [0m
[31mhepatic studies should be performed. Appropriate tests for autoimmune syndromes should be performed as indicated.         [0m
[31mSOURCE:MINOCYCLINE label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: Yes, MINOCYCLINE has been reported to increase the risk of angioedema. This adverse reaction is listed under postmarketing experiences with the drug, which means it has been observed after the[0m
[32mdrug was approved and released to the market.[0m

[32mSOURCE: MINOCYCLINE label[0m
[32mEXTRACT_START_END: [0m[32m...[0m[32mhypersensitivity reactions, angioneurotic edema[0m[32m...[0m
*[1m([0morchestrator-angioedema-MINOCYCLINE[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: Yes, MINOCYCLINE has been reported to increase the risk of [0m
[34mangioedema. This adverse reaction is listed under postmarketing experiences with the drug, which means it has been observed after the drug was approved and released to the market.[0m

[34mSOURCE: MINOCYCLINE label[0m
[34mEXTRACT_START_END: [0m[34m...[0m[34mhypersensitivity reactions, angioneurotic edema[0m[34m...[0m
 [1m([0morchestrator-angioedema-MINOCYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-angioedema-MINOCYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-angioedema-MINOCYCLINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does MINOCYCLINE increase or decrease the risk of angioedema?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler whether MINOCYCLINE increases the risk of angioedema."[0m[32m,[0m
[32m      [0m[32m"FDAHandler confirmed that MINOCYCLINE has been reported to increase the risk of angioedema, and this information is listed under postmarketing experiences in the drug label."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"MINOCYCLINE has been reported to increase the risk of angioedema."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-angioedema-MINOCYCLINE[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-angioedema-MINOCYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-angioedema-MINOCYCLINE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-angioedema-MINOCYCLINE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does MINOCYCLINE increase or decrease the risk of angioedema?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler whether MINOCYCLINE increases the risk of angioedema."[0m[34m,[0m
[34m      [0m[34m"FDAHandler confirmed that MINOCYCLINE has been reported to increase the risk of angioedema, and this information is listed under postmarketing experiences in the drug label."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"MINOCYCLINE has been reported to increase the risk of angioedema."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does MINOCYCLINE increase or decrease the risk of angioedema?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler whether MINOCYCLINE increases the risk of angioedema.[0m
[1;31m2[0m[31m. FDAHandler confirmed that MINOCYCLINE has been reported to increase the risk of angioedema, and this information is listed under postmarketing experiences in the drug label.[0m
[31m        -----[0m
[31m        Final answer: MINOCYCLINE has been reported to increase the risk of angioedema.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-angioedema-MINOCYCLINE[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-angioedema-MINOCYCLINE[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-angioedema-MINOCYCLINE[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-angioedema-MINOCYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-angioedema-MINOCYCLINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mThe final answer is that MINOCYCLINE has been reported to increase the risk of angioedema. This information comes from postmarketing experiences listed in the drug label.[0m
